VEGFR2
also: KDR, Kinase insert domain receptor
Vascular Endothelial Growth Factor Receptor 2, the primary signaling receptor mediating angiogenesis and endothelial cell survival downstream of VEGF.
VEGFR2 (Vascular Endothelial Growth Factor Receptor 2), also known as KDR or Kinase insert domain receptor, is a transmembrane receptor tyrosine kinase expressed mainly on endothelial cells. It is the main transducer of VEGF-A signalling and a dominant driver of new blood vessel formation in both normal and disease settings.
Why it matters in peptide research
VEGFR2 activation starts a cascade of intracellular events, including the PI3K/Akt, MAPK/ERK and eNOS pathways, that together promote endothelial cell proliferation, migration and tube formation. Without enough VEGFR2 signalling, tissue recovering from injury is described as unable to establish the blood supply that delivers oxygen and nutrients to regenerating cells.
In peptide research VEGFR2 appears in proposed explanations of how a compound might promote healing in wound, muscle and tendon models. Those explanations are hypotheses drawn mainly from cell and animal work. The receptor is also a target for drugs that act in the opposite direction, and a mechanism that promotes angiogenesis raises a safety question as well as a hope for repair.
The signalling cascade in detail
- VEGF-A dimer binds two VEGFR2 monomers, inducing receptor dimerisation.
- Trans-autophosphorylation of cytoplasmic tyrosine residues, particularly Y1175 and Y1214, creates docking sites for downstream effectors.
- PLCγ pathway (via Y1175) activates PKC and the MAPK/ERK cascade, which drives proliferation.
- PI3K/Akt pathway promotes endothelial cell survival and vascular permeability.
- eNOS activation generates nitric oxide, which mediates vasodilation and vessel-tone modulation.
- TSAd / Src pathway (via Y951) drives cell migration and lamellipodium formation.
- Receptor internalisation and lysosomal degradation provide negative-feedback termination.
Therapeutic relevance, both directions
VEGFR2 signalling is the target of anti-angiogenic drugs: bevacizumab binds VEGF-A, and the multi-kinase inhibitors sunitinib and pazopanib, which are cancer drugs, inhibit VEGFR2 kinase activity directly. The rationale offered for tissue-repair peptides runs the other way, toward promoting angiogenesis, and that rationale is a hypothesis.
Peptides and stacks that invoke this receptor
- BPC-157 — a 2025 review of BPC-157 in musculoskeletal healing says it "activates several overlapping pathways, notably VEGFR2 and nitric oxide synthesis via the Akt-eNOS axis". A cell study of rat tendon fibroblasts on its page reports effects on migration and survival through the FAK-paxillin pathway and does not report an effect on VEGFR2. A 2026 review says VEGFR2 activation and sustained angiogenic signalling are linked to tumour vascularisation in cancer, and that BPC-157's properties "raise a theoretical concern: BPC-157 could facilitate tumor vascularization in subjects with hidden or existing malignancy". That is a theoretical concern, not a finding in people. FDA's page "Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks" (content current as of 22 April 2026) says: "Compounded drugs containing BPC-157 may pose risk for immunogenicity for certain routes of administration and may have complexities with regard to peptide-related impurities and active pharmaceutical ingredient (API) characterization."
- TB-500 — a synthetic seven-amino-acid fragment (Ac-LKKTETQ) of thymosin beta-4, not the full-length protein; FDA's page names only the fragment, written LKKTETQ. FDA's bulk drug substances page (content current as of 22 April 2026) says: "Compounded drugs containing thymosin Beta-4, Fragment (LKKTETQ) may pose risk for immunogenicity for certain routes of administration due to the potential for aggregation as well as peptide-related impurities."
- GHK-Cu — a copper tripeptide used in skin-care products. The human trials found are nearly all topical, and two reports describe scalp injections of multi-ingredient formulations that include copper tripeptide. A 2026 review says: "Angiogenesis is beneficial in ischemic and diabetic wounds but may be undesirable in tumors, proliferative retinopathies, or vascular malformations. Any systemic or injectable program should therefore include context-specific angiogenic safety assessment." FDA's bulk drug substances page (content current as of 22 April 2026) says: "Compounded injectable drugs containing GHK-Cu may pose risk for immunogenicity due to the potential for aggregation and peptide-related impurities."
- The BPC-157 + TB-500 combination evidence review and the BPC-157 + TB-500 + GHK-Cu tissue-repair review both discuss VEGFR2-axis claims.
- See also the angiogenesis / VEGFR2 mechanism map.
Common misconceptions
VEGFR2 activation is sometimes conflated with unrestricted tumour-promoting angiogenesis. Receptor signalling in normal tissue is regulated, for example by receptor internalisation and negative feedback. The same 2026 review calls exogenous pro-angiogenic stimulation "a theoretical oncological risk for any compound acting through VEGF-related pathways". See the contraindication deep-dive.
- Correction (2026-11-06): Corrected 6 November 2026 after a citation audit: TB-500 is a fragment, not thymosin beta-4, and its VEGF claim was removed with unsourced BPC-157 receptor statements and assurances of self-limiting angiogenesis; a 2026 review's tumour-vascularisation concern and FDA's safety statements were added.
If you spot an error or have new evidence to suggest, please use our corrections policy.
Related glossary entries
VEGF (Vascular Endothelial Growth Factor)
A family of secreted glycoproteins that drive angiogenesis, vasculogenesis, and vascular permeability by activating VEGF receptors on endothelial and progenitor cells.
G-actin sequestration
The binding and buffering of monomeric globular actin (G-actin) by sequestering proteins, regulating the cytoplasmic pool available for actin filament polymerization and cell motility.